Introduction
In the mid-2000s, unregulated designer synthetic cathinones (SC) appeared on the recreational drug market (1, 2) as alternatives to the controlled stimulants-amphetamines, MDMA and piperazine derivatives. SC became known among the general public as 'bath salts', and were widely abused (1-3). Cases of severe intoxication and death were reported (4, 5) . The most commonly available drugs in this group-mephedrone, methylone and methylenedioxypyrovalerone (MDPV)-were banned in the USA (6) in 2011 and in many countries worldwide. New varieties of structurally related designer SC have emerged (1 -3). Data are available on pharmacology of some SC (7 -10) , but most of them have not been studied in detail. They are assumed to have stimulating effects (1, 2, 11, 12) similar to those of amphetamines, cocaine, MDMA and structurally related classic cathinones: methcathinone, cathinone, diethylpropion and pyrovalerone. The need to control the abuse of SC encourages testing laboratories to develop methods for their detection. Currently, gas chromatography -mass spectrometry (GC -MS) and liquid chromatography -tandem mass spectrometry (LC -MS-MS) are the methods of choice and should delineate the metabolism of SC. Traditional cathinone, methcathinone and diethylpropion are known to metabolize extensively into respective ephedrines and norephedrines (13) (14) (15) (16) (17) (18) (19) , and the parent drugs are detected in urine for only a short period of time after administration. In order to develop efficient testing methods, the extent of metabolism of newer SC must be determined and, if possible, the metabolites be synthesized for use as reference material. Various working groups investigated metabolism of selected SC in vitro with liver microsomes (20 -23), in rat urine (22 -25) and in humans (22, 25 -28) . The data are summarized in reviews (29, 30) .
Mephedrone (4-methylmethcathinone, 4-MMC), b-keto analog of methamphetamine, first synthesized in 1929 (31) , had no use until late 2000, when it became available as a drug. 4-MMC was reported the most commonly used SC (1) until legislation to control its abuse was adopted in Europe and USA (6) . Urinary metabolites were studied by Meyer et al. in rats and in a human sample (27) . N-Demethylation to primary amine was the major route with subsequent reduction of the keto-moiety into isomeric 4-methylnor-ephedrines and hydroxylation of the 4-methyl group in the aromatic ring followed by conjugation or oxidation to the respective carboxylic acid. Buphedrone is the next consequent homolog of methcathinone. It was first synthesized in 1928 (32) and emerged as a designer drug and replacement for mephedrone in 2010 (1). Chemical and spectral analysis of buphedrone was performed by Maheux and Copeland (33) , who synthesized reference materials in order to confirm identity of designer drugs in seized shipments. Pentedrone is the next consequent homolog of buphedrone. Its detailed chemical analysis and spectral characterization was performed by Maheux and Copeland (33) and Westphal et al. (34) . 4-Methyl-N-ethylcathinone (4-MEC), a second generation SC, was designed for replacement of mephedrone (2, 11). Jankovics et al. (35) developed a screening LC-MS-MS method for its detection, as a parent drug. Arrival of 3,4-dimethylmethcathinone (DMMC) on the designer drug market was first announced in 2010 (2) . Comprehensive characterization of a seized DMMC sample was reported by Locos et al. (36) . Flephedrone (4-fluoromethcathinone, 4-FMC) and its positional isomer 3-fluoromethcathinone (meta-fluoromethcathinone, 3-FMC) are also second generation SC, which arrived on the market in 2009 (37). 3-FMC preparation in a seized drug sample was characterized with NMR analysis, GC -MS and GC -MS-MS by Westphal et al. (38) . Metabolism of 3-FMC was studied with rabbit liver slices by Pawlik et al. (21) and in rat and with human liver microsomes by Meyer et al. (23) who found N-demethylated and b-reduced metabolites. Ethcathinone (N-ethylcathinone) is a principle metabolite of an old drug diethypropion (16) (17) (18) . Ethcathinone was reported responsible for its stimulating effect (19) . Ethcathinone's appearance as a recreational drug is recent (7) . Metabolic carbonyl reduction to ethylephedrine, ethyl-c-ephedrine and consequent N-dealkylation to norephedrine and phenylpropanolamine were reported (16) (17) (18) (19) . Methylone (3,4-methylenedioxymethcathinone, b-ketomethylenedioxymethamphetamine, bk-MDMA) was originally patented by Jacob and Shulgin (39) as an anti-depressant in 1996. In the mid-2000s, it became a widely abused recreational drug. Its pharmacological properties are documented (7 -9) . Studies on methylone metabolism in urine were performed in rat and humans (25, 27 -30) with an emphasis on phase II conjugated metabolites. Demethylenation was the major metabolic route with further conversion to 4-hydroxy-3-methoxymethcathinone and 3-hydroxy-4-methoxymeth-cathinone and subsequent conjugation. The minor metabolites were methylenedioxyephedrine, methylendioxy-c-ephedrine; and N-desmethyl metabolite-methylendioxycathinone (normethylone). Ethylone (3,4-methylenedioxy-N-ethylcathinone, MDEC, b-keto-methylenedioxyethylamphetamine, bk-MDEA), N-ethyl version of methylone, is a rare second generation designer cathinone. Metabolites found in human urine (26, 30) were similar to those of methylone. Demethylenation with subsequent O-methylation in the aromatic ring and conjugation were the major routes. Keto reduced and N-desalkylated products were the minor. Butylone (b-keto-N-methylbenzodioxolylbutylamine, bk-MBDB) is the next consequent homolog of methylone and a positional isomer of ethylone. It follows metabolism of methylone and ethylone (26, 27, 29, 30) . Pentylone (b-keto-methylbenzodioxolylpentanamine, bk-MBDP) is a homolog of methylone and butylone. Pentylone was originally patented as a stimulant (39) and was recently identified in a 'legal high' product, NRG-1, in a mixture with other cathinones (40) . a-Pyrrolidinopentiophenone (a-pyrrolidinovalerophenone, PVP) was reported as a novel designer drug in Germany (24) and as a replacement for the banned MDPV. PVP is closely related to the old prescription stimulant pyrovalerone, from which it differs by lacking a 4-methyl group. Metabolism was studied in detail in rat urine (24) . Eleven metabolites were identified including conjugates of multiple hydroxylation products. An obscure stimulant a-pyrrolidinobutiophenone (PBP) was first synthesized and patented (41) in Germany in the 1960s along with its homologs a-pyrrolidinopropiophenone (PPP) and PVP. Metabolism was studied by Meyer and Maurer (29) . Information on its recent use, dosages and psychotropic effects can be found on the Internet. Structurally, MDPV is a methylenedioxy derivative of PVP. It was characterized by MS and NMR (42) . Clinical, pharmacological and toxicological information on MDPV was summarized by Coppola and Mondola in a recent review (10) . Metabolism of MDPV was studied in vitro using human liver microsomes and in rat and human urine (22) . The sequence of demethylenation, O-methylation and conjugation is the major metabolic route. Other conjugated products resulted from oxidation in the side chain and in the pyrrolidine ring.
The following results on metabolic profiles of 16 SC in humans are obtained from large-scale testing of random urine samples originating from potential users in the USA. This provided a unique opportunity to evaluate the range of abused SC, to identify metabolites of new SC varieties, to assess the extent of metabolism and to select analytes for routine screening.
Experimental
A total of 34,561 urine specimens from various clients in the USA were submitted to Redwood Toxicology Laboratory (Santa Rosa, CA, USA) over the period February 2011 -January 2013 for designer stimulant screening. There was no prior specimen information about drug(s) ingested, time of use before urine collection, donor's age, gender ethnicity, etc.
Free compounds were extracted with 6 mL of methyl-tertbutyl ether (MtBE) from 2 mL of urine alkalinized with 1 g of solid buffer NaHCO 3 /Na 2 CO 3 (3:2). Dry extract residues were derivatized with 100 mL of trifluoroacetic anhydride in 100 mL of ethyl acetate at 658C for 15 min. After solvent/reagent evaporation, specimens were reconstituted with 100 mL of ethyl acetate, vialed and 1 mL aliquots were injected into GC -MS.
Agilent 5975/6890 GC -MS was used. Gas chromatographic conditions were as follows: fused silica column Agilent CP7684 10m Â 0.15 mm i.d., methyl-silicon stationary phase film thickness 0.12 mm; hydrogen carrier gas constant flow 1 mL/min; initial column temperature 808C (0.1 min), 328C/min ramp to 1458C (0 min), 558C/min ramp to 3008C (hold 0.2 min); split mode injection at 2658C, 16:1 split ratio. The mass spectrometer was operated in EI mode, acquiring full spectra in m/z 43 -450 mass range. Kovats retention indices (RI) were obtained by running a mixture of normal hydrocarbons along with the compounds of interest.
Reference cathinones were purchased from Cerilliant, Cayman Chemicals, Sigma and Lipomed: buphedrone; butylone; cathinone; DMMC; ethcathinone; N-ethyl-buphedrone; ethylone; eutylone; flephedrone (3-FMC and 4-FMC); methcathinone; mephedrone; methedrone; 4-methyl-buphedrone; MDPV; 4-methyl-N-ethyl-cathinone (4-MEC); methylone; naphyrone; pentedrone; pentylone; PBP and PVP. Metabolites of some SC were purchased from Cerilliant (4-methylephedrine and 'buphedrine'-buphedrone metabolite) and from Lipomed (4-fluoroephedrine and 4-methyl-N-ethylnorephedrine).
Routine urine samples, containing parent SC and samples exhibiting unusual chromatographic profiles, were further investigated for potential metabolites excreted free in urine.
Results
Representative extracted ion chromatogram of a TFA derivatized urine extract after presumed administration of mephedrone is shown in Figure 1 . Identification of metabolites was postulated on the basis of their electron impact (EI) mass spectra, which are also shown in the Figure 1 . Minor peak of parent mephedrone (f) is preceded by its abundant metabolites: two pairs of diastereomers, partially resolved 4-methylnorephedrine/4-methylnor-c-ephedrine (a, b) and well-separated 4-methylephedrine/4-methyl-cephedrine (c, e). Mass spectra within each pair of diastereomers were very similar. Therefore, one spectrum for each pair is shown. Mass spectrum and retention time of TFA-derivatized 4-methyl-ephedrine standard from Cerilliant match compound c, which makes identification of this metabolite definitive.
Chromatograms and mass spectra of TFA derivatized urine extracts after presumed administration of buphedrone (Supplementary data, Figure S1 Figure S8 ) can be found in Supplementary data. Excretion patterns for this group of cathinones were similar to the one of mephedrone.
Representative extracted ion chromatogram of a TFAderivatized urine extract after presumed administration of methylone is shown in Figure 2 . Identification of minor metabolites was also postulated based on their mass spectra (Figure 2) . Peaks of minor metabolites (ar, as, at and au) are followed by abundant parent methylone (av). Chromatograms and mass spectra of TFA derivatized urine extracts after presumed administration of ethylone (Supplementary data, Figure S9) ; butylone (Supplementary data, Figure S10 ) and pentylone (Supplementary data, Figure S11 ) are located in Supplementary Data. Excretion profiles in this group of drugs are similar to that of methylone.
Representative extracted ion chromatogram of a TFAderivatized urine extract after presumed administration of PBP is shown in Figure 3 , which also contains mass spectra of a parent drug and proposed metabolites. Similar results were observed for PVP (Supplementary data, Figure S12 ). Metabolic profiles of these two drugs differ from the previous groups of cathinones. Metabolites are presumably identified as products of pyrrolidine ring degradation to the primary amine and carbonyl reduction to respective alcohols. Direct products of b-keto reduction with intact pyrrolidine ring were not found. Free metabolites of significant abundance were not found in MDPV positive urine samples (Supplementary data, Figure S13 ).
Positivity rates for specific cathinones and some other designer stimulants in routine testing of 34,561 random urine samples are shown in Table I .
Synthetic cathinones and their presumed metabolites, found in this study, are presented in Table II in the order of chromatographic elution (RI).
Discussion
Testing a large number of random human urine samples for designer stimulants revealed characteristic patterns of metabolites and parent drugs, consistent with the use of various SC available on the USA market from February 2011 to January 2013. Parent cathinones in urine were identified by matching their mass spectra and retention to the commercially available reference standards. Metabolites' structures were postulated on the basis of mass spectra, chromatographic retention and existing data on the known metabolism of related classic cathinones. On a few occasions, metabolites' structural assignments were confirmed by parallel analysis of synthesized reference substances. This work does not present true excretion studies. Limitations to this study include unknown time of ingestion, amount of ingestion, co-administration of other drugs and consideration of only free excreted drugs and metabolites. This, in particular, limited our ability to determine windows of detection and relative longevity of metabolites in urine after ingestion of various cathinones.
A Group 1 of nine synthetic designer cathinones: mephedrone, buphedrone, 4-methylbuphedrone, pentedrone, 4-methyl-Nethylcathinone, DMMC, N-ethylbuphedrone, flephedrone and ethcathinone ( Figure 4 ) appear to follow metabolic path of classic drugs: cathinone (13 -15) , methcathinone (17) and diethylpropion (16, 18, 19) into respective alcohols-substituted ephedrines and norephedrines. Indeed, products consistent with metabolic reduction of b-keto group and consequent N-dealkylation are found in all urine samples, containing parent drugs (Figure 1 ; Supplementary data, Figures S1 -S8 ). Parent drugs were less abundant than metabolites or not present at all, indicating the high extent of metabolism. Keto-reduction forms two diastereomeric alcohols with varying relative abundances. Further N-dealkylated alcohols (substituted norephedrines) were the most abundant metabolites. Patterns of four peaks, two diastereomeric ephedrines and two diastereomeric norephedrines, formed characteristic profiles for each cathinone in Group 1. Substituted norephedrines were often found in urine alone without a parent drug and respective ephedrines, which may likely indicate their relatively high longevity. N-Nor metabolites with intact b-keto group (N-nor cathinones) were rarely detected and only in highly concentrated samples, likely representing recent ingestion. For this group of cathinones, b-keto reduced metabolites appear the essential markers of the parent drug use. It should be noted that two pairs of alcohols forming a pattern of four peaks for each SC in Group 1 may represent eight possible isomeric structures, four diastereomers and four enatiomers, of which diastereomers are separated by GS, as TFA derivatives.
Four recently introduced commercial reference standards were available to confirm identity of four SC metabolites found in this study: 4-fluoroephedrine (aj -flephedrone metabolite), 4-methylephedrine (c -mephedrone metabolite), 4-methyl-N-ethylephedrine (x -4-MEC metabolite) and 2-methylamino-1-phenylbutan-1-ol (i -buphedrone metabolite). Matching mass spectra and RI make their identification definitive. Identification of all other metabolites is considered presumptive.
A Group 2 of 3,4-methylenedioxy-substituted cathinones (methylone, ethylone, butylone and pentylone) appears to metabolize by b-keto reduction to a much lower extent ( Figure 5 ). Parent drugs dominate chromatograms (Figure 2 ; Supplementary data, Figures S9 -S11) . Identified metabolites are similar to those in the previous group: keto-reduced and N-dealkylated products, but much less abundant. Methylendioxy addition to the aromatic ring seems to restrict metabolic carbonyl reduction. Concurrent metabolic demethylenation can also be a contributing factor. Routine screening for this group of cathinones in free urine fraction should rely on the detection of parent drugs. Metabolites resulting from demethylenation, O-methylation and conjugation (25 -30) cannot be detected by this procedure.
A Group 3 of pyrrolidiniphenones, PBP and PVP ( Figure 6 ) appear not to metabolize directly by keto-reduction into alcohols, likely due to pyrrolidine ring hindrance. In free urine fraction, PBP and PVP are found unchanged and as metabolites, pyrrolidine degradation products to primary amine (24) further reduced to alcohols (Figures 3 and 6 ; Supplementary data, Figure S13 ). Free parent compounds and metabolites are both abundant in urine.
Methylenedioxypyrrovalerone (MDPV) is detected in urine as such with no free excreted metabolites (Supplementary data, Figure S13 ). Both pyrrolidine ring and methylenedioxy group inhibit carbonyl reduction.
Accurate assignment of some detected metabolites to a specific parent cathinone may not always be possible, because they may be shared by more than one drug. In particular N-dealkylated ephedrines, which have lost a part of the original identity, can derive from more than one parent cathinone. For instance, diastereomeric 4-methylnorephedrines (compounds a and b in Figure 1 ; Supplementary data, Figure S4 ) can be metabolic products of mephedrone, 4-MEC or PPP. Buphedrone, ethylbuphedrone and PBP (Supplementary data, Figures S1 and S6; Figure 3 ) share metabolites g and h ; pentedrone and PVP-metabolites r and s (Supplementary data, Figures S3 and S13 ). In these cases, exact identification of a parent drug should include non-dealkylated substituted ephedrines, which retain intact N-alkyl radicals.
As follows from Table I , the most prevalent SC during 2-year period of testing were PVP, MDPV and pentedrone. MDPV was mostly found in 2011 until its ban in the USA in October 2011. It was later replaced by pentedrone and PVP. Surprisingly, mephedrone was among rarely found cathinones with only 0.04% positivity rate. Positivity for individual drugs varied over time, reaching up to 10% for PVP and MDPV during peak of abuse periods. Previously popular designer stimulants, such as methylenedioxymethamphetamine (MDMA), benzylpiperazine (BZP) and r-methoxymethamphetamine (PMMA), were extremely rare (Table I) , suggesting declined usage.
This study provides useful information for screening of various SC in human urine by GC -MS. Large number of available cathinones, each producing multiple metabolites with similar structures and mass spectrometric fragmentation demands efficient chromatographic separation. Analytes, found in this study and presented in Table I , show potential density of chromatographic peaks to be resolved, when multiple drugs are used. GC -MS approach offers advantage of fast and efficient separation, crucial for successful identification of analytes in such complex mixtures. Analyzing free drugs and metabolites, as opposed to conjugated, provides additional advantage of clean extracts, cleaner less complicated chromatograms, reduced GC -MS system contamination and reduced equipment maintenance.
Supplementary data
Supplementary data are available at Journal of Analytical Toxicology online.
